Ivermectin, an antiparasitic drug, has been at the center of discussions regarding its potential use beyond its approved applications, particularly for treating COVID-19 and cancer.
Various individuals, including medical professionals and laypeople, have shared personal anecdotes and professional opinions suggesting that Ivermectin could be effective against these conditions.
Some claim it has been used successfully to treat severe COVID-19 cases, with stories of doctors using it when conventional treatments failed. There are also assertions that Ivermectin might inhibit cancer growth, similar to its effect on parasites. However, skepticism persists due to scientific studies indicating that the effective doses in vitro are toxic to humans.
Despite these findings, there is a belief among some that the drug’s potential has been downplayed due to its low cost and lack of profitability for pharmaceutical companies.
The debate also touches on broader issues like medical decision-making, the role of regulatory bodies like the FDA, and the influence of the pharmaceutical industry on health policies.
